Annals of the Rheumatic Diseases, 79, 6, pp. 685-699 Smolen, J S, Landewé, R B M, Bijlsma, J W J, Burmester, G R, Dougados, M, Kerschbaumer, A, McInnes, I B, Sepriano, A, Van Vollenhoven, R F, De Wit, M, Aletaha, D, Aringer, M, Askling, J, Balsa, A, Boers, M, Den Broeder, A A, Buch, M H, Buttgereit, F, Caporali, R, Cardiel, M H, De Cock, D, Codreanu, C, Cutolo, M, Edwards, C J, Van Eijk-Hustings, Y, Emery, P, Finckh, A, Gossec, L, Gottenberg, J E, Hetland, M L, Huizinga, T W J, Koloumas, M, Li, Z, Mariette, X, Müller-Ladner, U, Mysler, E F, Da Silva, J A P, Poór, G, Pope, J E, Rubbert-Roth, A, Ruyssen-Witrand, A, Saag, K G, Strangfeld, A, Takeuchi, T, Voshaar, M, Westhovens, R & Van Der Heijde, D 2020, ' EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update ', Annals of the Rheumatic Diseases, vol. 79, no. 6, pp. S685-S699 . https://doi.org/10.1136/annrheumdis-2019-216655 Annals of the Rheumatic Diseases, 79(6), S685-S699. BMJ Publishing Group Annals of the rheumatic diseases, 79(6), S685-S699. BMJ Annals of the rheumatic diseases, 79(6), S685-S699. BMJ Publishing Group Annals of the Rheumatic Diseases, 79, 685-699 Annals of the Rheumatic Diseases, Vol. 79, No 6 (2020) pp. 685-699